Antengene gets Australian HREC nod to initiate phase I trial of ATG-018 to treat advanced solid tumours and hematologic malignancies
Antengene Corporation Limited, a leading commercial-stage global biopharmaceutical company, announced that it has received approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate the phase I trial of ATG-018 in patients with advanced solid tumours and hematologic malignancies (ATRIUM Trial). ATG-018 is an orally-available, potent, selective small molecule ATR inhibitor. ATG-018 inhibits the ATR kinase, thus limiting cancer cells
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
